Cancer is the result of mutagenic processes that can be inferred from genome sequences by analysis of mutational signatures. Here we present SparseSignatures, a novel framework to extract mutational signatures from somatic point mutation data. Our approach incorporates DNA replication error as a background, enforces sparsity of non-background signatures, uses cross-validation to identify the number of signatures, and is scalable to very large datasets. We apply SparseSignatures to whole genome sequences of 2827 tumors from 20 cancer types and show by standard metrics that our set of signatures is substantially more robust than previously reported ones, having eliminated redundancy and overfitting. Known mutagens (e.g., UV light, benzo(a)pyrene, APOBEC dysregulation) exhibit single signatures and occur in the expected tissues, a dominant signature with uncertain etiology is present in liver cancers, and other cancers exhibit a mixture of signatures or are dominated by background and CpG methylation signatures.
Introduction contain very few mutations, which makes it difficult to discover reliable signatures and leads to stochastic noise. To illustrate this, we applied two signature discovery methods to a liver cancer dataset 16 , using, first, whole-genome data, and second, only mutations in exons ( Supplementary   Figures 2 and 3 ). Using only exons, the number of signatures is lower, background noise is higher, and the signatures differ from those obtained using the whole genome. Since there are no criteria defining a sufficient number of mutations, even whole-genome sequences with few mutations may be insufficient for de novo signature discovery.
(2) NMF methods aim to minimize the residual error after fitting the dataset with the discovered signatures. This does not necessarily produce well-differentiated signatures, nor does it minimize noise in the signatures. A method that favors sparsity of the signatures in addition to minimizing residual error would help alleviate these drawbacks. In addition, enforcing sparsity has a biological rationale on the basis of biochemical mechanism: Most mutagens 17, 18 are highly specific in the type of damage they cause, and we therefore expect a majority of somatic mutational signatures to be sparse.
(3) No method incorporates the natural background of 'standard' replication error, which occurs in the normal course of cell division both in the germline and in somatic cells, including those of a tumor 19 . Since we expect it to be present in all samples, and since most tumor cell lineages have undergone very large numbers of cell divisions, it should be considered a constant signature. If unaccounted for, replication error will likely find its way into other signatures, diminishing their accuracy.
(4) NMF-based methods require the number of signatures as an input parameter but lack a principled basis for its selection. Discovering more signatures will always tend to improve the fit, i.e.
explain the observed data better. However, the goal of signature discovery is not to fit the data as well as possible, but instead to identify signatures that are truly likely to reflect separate biological processes. Currently, ways to choose the number of signatures include: adding signatures until residual error is no longer significantly reduced (this is decided by human inspection and can be highly ambiguous) and evaluating reproducibility of the signatures 15 , and calling signatures hierarchically on subsets of samples in order to fit every sample 9 .
SignatureAnalyzer uses automatic relevance determination, starting with a high number of signatures and attempting to eliminate signatures of low relevance 20 . These methods aim to select as many signatures as needed to improve fitting of the data, with no constraint to prevent overfitting. Overfitting can lead to many similar signatures that actually represent the same process distorted by noise; such signatures are therefore limited in their usefulness. Moreover, with multiple similar signatures it is difficult to reliably attribute mutations in a sample to any one signature, leading to misinterpretation of the results and possibly misleading conclusions.
To overcome these drawbacks, we developed SparseSignatures (Figure 1a 
Results
SparseSignatures is implemented in R and is available online as a Bioconductor package at https://bioconductor.org/packages/release/bioc/html/SparseSignatures.html. Noteworthy innovations are:
1. It incorporates an explicit background model (Figure 1b ) based on the human germline mutation spectrum 21 , with an empirical adjustment to CpG > TpG mutation rates. This is because CpG > TpG mutations are frequently caused by CpG methylation, which can vary greatly in cancer cells, and are therefore not perfectly correlated with replication rates in tumors. SparseSignatures fixes the background signature and then discovers additional signatures representing cancer-specific mutagenic processes (including, usually, CpG methylation).
2. It uses the LASSO 22 to enhance sparsity and reduce noise in the signatures, except for the fixed background signature. The extent to which sparsity is favored is controlled by a tunable parameter, λ. The value of λ is learned to avoid forcing excessive sparsity. Remarkably, most of the signatures can be associated with a known mutational process ( Table 4 ). Our signatures are considerably sparser than the other sets, and also show the lowest similarity between signatures, indicating that they are more clearly differentiated from each other. Moreover, our signatures show the lowest similarity between background (replication error) signature and the non-background signatures, suggesting that the other sets contain noise in the signatures due to improper separation from the DNA replication errors. These results demonstrate the value of sparsity and of explicitly separating the background.
While our approach is not the first to emphasize sparsity, it is the first to combine sparsity with a fixed background and principled discovery of the number of signatures. Without a fixed background, increasing sparsity may prevent detection of the background replication error signature due to its dense nature. We ran other methods for sparse signature discovery Table 5) .
Surprisingly, the clusters are only moderately associated (NMI=0.39) with the tissue of origin; barring a few clusters linked to a single tissue and mechanism (such as cluster 9, which is composed of skin melanomas dominated by signature 8, i.e., UV light), the majority of clusters show distinct patterns of signatures but span several cancer types. For example, almost all esophageal and many gastric cancers fall into two clusters: cluster 8, which is dominated by signature 9 (tentatively linked to gastroesophageal reflux 27 ), and cluster 9, which shows high contributions from both signature 7 (cytosine methylation) and signature 9. However, many gastric cancer cases also fall into cluster 16, which is a mixed cluster, including pancreatic and prostate tumors, that is dominated by the methylation signature. Interestingly, skin melanomas also fall largely into two clusters: cluster 9, which is dominated by signature 8 (UV light) and cluster 10, which is more diverse, with high contributions from both the background and signature 2.
Discussion
SparseSignatures is a novel approach designed to discover the best number of clearly differentiated signatures with minimal background noise, which have robust statistical support by repeated cross-validation on unseen data points and are not likely to be the result of overfitting.
Using SparseSignatures on data from 20 cancer types, we obtain 9 signatures in addition to the background. The dramatic difference in number compared to previous methods and studies 2, 12 reflects the perennial issue of the balance between sensitivity and specificity. It is possible that our method does not find some signatures that make very small contributions to the dataset. However, while overfitting may capture weakly represented signatures, it can and does lead to a proliferation of misleading results that detract from attention to the most important signals. SparseSignatures selects the signatures that perform best at fitting unseen data points, allowing us to focus on high-confidence signatures. This also allows us to avoid post hoc processing of the discovered signatures which introduces ambiguity and bias. We suggest, on the basis of our methodological innovations that prevent overfitting and utilize best practices in inference, that there may be less complexity in the repertoire of human cancer mutational signatures than previously thought.
Consistent with biological expectation, the contribution of DNA replication error (the 'background' signature) is the predominant cause of point mutations in 13 of the 20 analyzed cancer types ( Figure 2 ). In five, CpG methylation is the predominant cause, suggesting that gene deregulation is a major contributor to, perhaps a driver of, the etiology of these tumors. Known mutagens (e.g., UV light or smoking) contribute in expected ways (e.g., melanoma and lung adenocarcinoma, respectively).
Remarkably, none of the signatures are similar to one another, highlighting the potential significance of signatures 1 and 2, which do not have known etiologies, but which, due to their sparsity, suggest highly specific chemical or cell biological mechanisms. Signature 1 seems particularly important to understand, as it is the largest non-background contributor to liver cancer, a usually aggressive disease. Similarly, clustering of the samples (Figure 4 ) suggests strongly that signature 1 is the main force behind a distinct liver etiology, as clusters 3-5, which are dominated by signature 1, contain most of the liver samples.
Also of note is signature 9, which defines esophageal and a subset of stomach cancers, and which has been associated with acid reflux, but for which the actual mutagen is unknown. This sparse signature, which is enriched in a very specific manner for T>G / A>C mutations in the CTT / AAG context, suggests a specific mutagen, as opposed to a more general mechanism. We suggest that this lead will spark interest in both epidemiological (for associations) and biochemical (for mechanism) communities to understand the cause. To enforce sparsity in the discovered signatures, we use the LASSO 22 . This is done by adding an additional regularization term to the cost function to be minimized:
The parameter controls the extent to which sparsity is encouraged in the signature matrix β. If λ the value of is set too low, it is ineffective, whereas if it is set too high, the signatures are forced to be λ too sparse and no longer accurately fit the data.
It should be noted that unlike the standard LASSO, the objective function we minimize here is non-convex. But it is bi-convex (convex in α with β fixed and vice-versa). Hence the alternating algorithm described below is natural and yields good solutions.
Implementation of SparseSignatures. SparseSignatures discovers mutational signatures by following
the steps below.
Step 1: Build the Count Matrix M by counting the number of mutations of each of the 96 categories in each sample.
Step 2 : Remove samples with less than a minimum number of mutations. In the analysis described in this paper, we have used a minimum number of 1000 mutations per tumor genome.
Step 3: Choose a range of values to test for K (number of signatures) and λ (level of sparsity).
Step 4: For each value of K in the chosen range, obtain a set of K initial signatures using repeated NMF 28 to obtain a more robust estimation. This is an initial value for the matrix β. We use these NMF results as a starting point (although other starting points such as randomly generated signatures may also be chosen) and further refine the signatures. In practice, the final discovered signatures are often very different from those produced by the initial NMF.
Step 5 5e. At the last iteration of step 5d, measure the mean squared error (MSE) of the prediction.
5f. Repeat the entire cross-validation procedure (steps 5a-5d) a number of times (set to 10 by default) and calculate the MSE for all cross-validations. Since we randomly select a different set of cells for cross-validation each time, this allows us to obtain a robust measure of MSE.
Step 6: Choose the values of K and λ that correspond to the lowest MSE in most of the cross-validations.
Step 7: Using the selected values for K and λ, repeat sparse signature discovery (step 5c) on the complete matrix M (without replacing any cells with 0). This generates the final values of α 0 , α and β.
Background signature. We used the germline mutation spectrum calculated by Rahbari et al 21 . We validated this independently using whole-genome sequencing data from normal tissue samples (see Supplementary Methods for details). We then adjusted the rates of ACG>ATG, CCG>CTG, GCG>GTG and TCG>TTG mutations to be equal to the rates of ACA>ATA, CCA>CTA, GCA>GTA and TCA>TTA mutations respectively, in order to separate the effects of DNA methylation from the background signature.
Definition of the λ parameter. This parameter tunes the desired level of sparsity to be obtained by LASSO. For any analysis by LASSO, one can compute a maximal value of the LASSO penalty after which all the coefficients of the regression get shrunk to zero 29 . As this maximal value can vary depending of the problem, our λ parameter represents the fraction of the actual maximal value to be used.
Values closer to 1 result in sparser signatures.
Pan-cancer dataset. We obtained a dataset of point mutations from Alexandrov et al. 12 that includes samples from PCAWG, ICGC and TCGA. We selected only whole-genome sequencing data and removed samples with less than 1000 point mutations. We also removed cancer types with less than 10 samples.
Finally, we removed samples with >50,000 mutations so that the signature extraction process is not biased toward these outliers. After this preprocessing, a total of 2827 samples from 20 different cancer types remained.
Software. The experiment carried out in this paper were performed using the SparseSignatures v1.0. 
